What could you do if your data was working for you and not against you? With Bloomberg delivering

enterprise data directly to your systems, you get easy access to the details you want, optimized for

higher level analysis, and financial data experts committed to helping you maximize your every move.

Our data is made for more, so you can show the world what you're made of.

Visit Bloomberg.com slash enterprise data to learn more.

Welcome to Prognosis. I'm Laura Carlson. It's day 347 since coronavirus was declared a global pandemic. Today's main story, the U.S. vaccination effort has ramped up to a pace of more than a

million shots a day. But second shots are coming due, putting pressure on states and leaving some

people hanging as they wait to get fully immunized. But first, here's what happened in

virus news today.

U.S. U.S. regulators called Johnson & Johnson's COVID-19 vaccine safe and effective.

It's a key milestone on the path toward giving Americans access to the first

such shot to work in a single dose. According to the Food and Drug Administration, which

reviewed the company's trial results, the vaccine was 72% effective in the U.S.-based trial arm of its global study.

The FDA found the vaccine to be effective against severe disease

and said it worked better against mutant coronavirus strains than previously reported.

New York City health officials said 6% of the city's coronavirus cases are due to the

UK variant, which is believed to be more contagious.

While that number is higher than officials liked, they said the number has remained steady in recent weeks.

Meanwhile, the city's middle school students will return to the classroom on Thursday,

bringing New York one step closer to a semblance of normalcy since the pandemic shuttered many school buildings for nearly a year.

High school buildings will remain closed.

Finally, the Czech Republic is preparing to impose a stricter lockdown to prevent the collapse of its medical system.

...